The Lynx Group

Conference Correspondent

News, views, and coverage of important topics and discussions from oncology conferences and events.

Conference Correspondent — October 16, 2020
Uncertainty reigns in Washington with the upcoming election only weeks away. What can cancer care stakeholders expect from legislators and policymakers over the next several weeks, during the lame duck session, and in 2021?
Read Article

Conference Correspondent — October 16, 2020
The top priority for employers regarding their employees’ cancer care coverage is ensuring access to state-of-the-art care. Learn how employers are trying to close the gap between “typical” and “optimal” care.
Read Article

Conference Correspondent — October 16, 2020
Telling the story of the Oncology Care Model and its performance over the past 5 years through some of the best-performing practices.
Read Article

Conference Correspondent — October 16, 2020
On October 8, 2020, the Berkeley Research Group published a report showing that contract pharmacy participation in the 340B Drug Pricing Program grew by 4228% between 2010, when the Health Resources and Services Administration expanded the contract pharmacy program, and 2020. A week later, on October 16, 2020, a variety of stakeholders in the 340B program—covered entities, contract pharmacies, pharmaceutical manufacturers, and outside tech consultants—participated in an intense discussion of contract pharmacy growth, newly imposed manufacturer audit requirements, and ways to return 340B to its original purpose of spreading scarce federal resources and serving vulnerable patients.
Read Article

ASCO 2020 Lung Cancer Highlights
Conference Correspondent — July 30, 2020

Although the American Society of Clinical Oncology (ASCO) 2020 meeting was held virtually because of the COVID-19 pandemic, hundreds of abstracts, posters, and presentations were still made available to inform clinicians on the latest developments in the treatment of lung cancer. This publication features some of the key highlights from the meeting, which can be used to improve the management and care of patients with the disease.

Read Article

Conference Correspondent — June 1, 2020
Immune-related adverse events did not affect the clinical benefit of consolidation checkpoint inhibitor therapy after chemoradiation in stage III non–small-cell lung cancer.
Read Article

Conference Correspondent — June 1, 2020
The frequency and durability of outcomes associated with acquired resistance to PD-1 inhibition in non–small-cell lung cancer are presented.
Read Article

Conference Correspondent — June 1, 2020
The characteristics of long-term responders to PD-1 blockade are presented.
Read Article

Conference Correspondent — June 1, 2020
For oncologists and others who advocate for smoking cessation, it is important to know whether recent quitters who are diagnosed with lung cancer can achieve a survival benefit.
Read Article

Conference Correspondent — June 1, 2020
Weekly epirubicin was evaluated as a potential “gentle” option for second-line chemotherapy in patients with malignant pleural mesothelioma after failure of first-line pemetrexed-based chemotherapy.
Read Article

Page 1 of 37

Subscribe to
Value-Based Cancer Care

Stay up to date with personalized medicine by subscribing to recieve the free VBCC print publication or weekly e‑Newsletter.

I'd like to recieve: